Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 7/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 2/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 2/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 2/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 2/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 2/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | GABRP | O00591 | 1/20 | 1.00 |
| ▸ | GABRD | O14764 | 1/20 | 1.00 |
| ▸ | IKBKB | O14920 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | TOP1 | P11387 | 1/20 | 1.00 |
| ▸ | IDO1 | P14902 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norharmane SCHEMBL9486853 | 1.00 | CHUK (1.00) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL25834 | 1.00 | CHUK (1.00) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Carbazole SCHEMBL18684843 | 1.00 | CHUK (1.00) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL11561251 | 0.98 | CHUK (0.96) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL21378153 | 0.98 | CHUK (0.96) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL8683826 | 0.98 | CHUK (0.96) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL30013210 | 0.98 | CHUK (0.96) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL8686167 | 0.98 | CHUK (0.96) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL29809643 | 0.98 | CHUK (0.96) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL29217000 | 0.98 | CHUK (0.96) | CHUKGABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 438 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137652-A1 | Composition Comprising Non-Phosphorylated Tryptamine | SINTALICA S R L (IT) | 2026-05-21 | — | — | US | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260069538-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-12 | — | — | US | claimed |
| US-20260049115-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | THE UNIVERSITY OF CHICAGO (US) | 2026-02-19 | — | — | US | claimed |
| EP-4646433-A1 | ANTI-IL-18BP ANTIBODIES | Lassen Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| EP-4646432-A1 | ANTI-IL-18BP ANTIBODIES | Lassen Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4638788-A1 | ANALYSIS OF ANALYTES AND SPATIAL GENE EXPRESSION | 10X Genomics, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4638419-A1 | NON-HALLUCINOGENIC TRYPTAMINE COMPOUNDS, PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sintalica S.r.l. (IT) | 2025-10-29 | — | — | EP | claimed |
| US-12453720-B2 | Application of norharmane in improving antibacterial activity of antibiotics | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2025-10-28 | — | — | US | claimed |
| EP-4229416-A1 | METHOD FOR DETECTION OF ANALYTES IN A SINGLE TISSUE SAMPLE FROM ITO SLIDES USING MSI-LCM | Universiteit Maastricht (NL) | 2023-08-23 | — | — | EP | claimed |
| CN-116270626-A | Application of nor Ha Erman in preparation of antibacterial agent | 浙江工业大学 | 2023-06-23 | — | — | CN | claimed |
| WO-2023081514-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-11 | — | — | WO | claimed |
| WO-2023076998-A1 | COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES | ATYR PHARMA, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| CN-114288291-B | Application of Norharman in preparation of medicine for preventing or treating acute pancreatitis | 大连医科大学附属第一医院 | 2023-04-28 | — | — | CN | claimed |
| US-20220304988-A1 | AN APPLICATION OF NORHARMANE IN IMPROVING ANTIBACTERIAL ACTIVITY OF ANTIBIOTICS | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2022-09-29 | — | — | US | claimed |
| EP-4037711-A1 | COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIES | Atyr Pharma, Inc. (US) | 2022-08-10 | — | — | EP | claimed |
| WO-2022094132-A1 | A SILICASOME NANOCARRIER FOR METAL-BASED DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022079084-A1 | METHOD FOR DETECTION OF ANALYTES IN A SINGLE TISSUE SAMPLE FROM ITO SLIDES USING MSI-LCM | UNIVERSITEIT MAASTRICHT (NL) | 2022-04-21 | — | — | WO | claimed |
| CN-107290452-B | Method for detecting content of bound heterocyclic amine | 江南大学 | 2022-04-15 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220304988-A1 | AN APPLICATION OF NORHARMANE IN IMPROVING ANTIBACTERIAL ACTIVITY OF ANTIBIOTICS | NRDC, MGAM, GALE | CHUK 1933/4885GABRA1 2797/4885GABRG2 3615/4885 |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | HMBS, SNCA, PYGB | CHUK 3736/4885GABRA1 667/4885GABRG2 1588/4885 |
| US-20260049115-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | FN1, MATR3, COL14A1 | CHUK 3684/4885GABRA1 2593/4885GABRG2 3047/4885 |
| US-20260137652-A1 | Composition Comprising Non-Phosphorylated Tryptamine | HTR2B, BDNF, HTR3B | CHUK 1809/4885GABRA1 280/4885GABRG2 748/4885 |
| US-20260069538-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | CXCL12, CXCR4, CXCR5 | CHUK 650/4885GABRA1 2384/4885GABRG2 3393/4885 |
| US-12453720-B2 | Application of norharmane in improving antibacterial activity of antibiotics | NRDC, NOTUM, MGAM | CHUK 2109/4885GABRA1 3103/4885GABRG2 3615/4885 |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | MAOA, MAOB, TPH1 | CHUK 2078/4885GABRA1 2398/4885GABRG2 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.